Literature DB >> 27026379

Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry.

Francesco Violi1, Gino Roberto Corazza2, Stephen Hugh Caldwell3, Francesco Perticone4, Angelo Gatta5, Mario Angelico6, Alessio Farcomeni7, Michela Masotti2, Laura Napoleone8, Annarita Vestri7, Valeria Raparelli8, Stefania Basili8.   

Abstract

Portal vein thrombosis may occur in cirrhosis; nevertheless, its prevalence, and predictors are still elusive. To investigate this issue, the Italian Society of Internal Medicine undertook the "Portal vein thrombosis Relevance On Liver cirrhosis: Italian Venous thrombotic Events Registry" (PRO-LIVER). This prospective multicenter study includes consecutive cirrhotic patients undergoing Doppler ultrasound examination of the portal area to evaluate the prevalence and incidence of portal vein thrombosis over a 2-year scheduled follow-up. Seven hundred and fifty-three (68 % men; 64 ± 12 years) patients were included in the present analysis. Fifty percent of the cases were cirrhotic outpatients. Viral (44 %) etiology was predominant. Around half of the patients had a mild-severity disease according to the Child-Pugh score; hepatocellular carcinoma was present in 20 %. The prevalence of ultrasound-detected portal vein thrombosis was 17 % (n = 126); it was asymptomatic in 43 % of the cases. Notably, more than half of the portal vein thrombosis patients (n = 81) were not treated with anticoagulant therapy. Logistic step-forward multivariate analysis demonstrated that previous portal vein thrombosis (p < 0.001), Child-Pugh Class B + C (p < 0.001), hepatocellular carcinoma (p = 0.01), previous upper gastrointestinal bleeding (p = 0.030) and older age (p = 0.012) were independently associated with portal vein thrombosis. Portal vein thrombosis is a frequent complication of cirrhosis, particularly in patients with moderate-severe liver failure. The apparent undertreatment of patients with portal vein thrombosis is a matter of concern and debate, which should be addressed by planning interventional trials especially with newer oral anticoagulants. Clinicaltrials.gov identifier NCT01470547.

Entities:  

Keywords:  Anticoagulants; Esophageal varices; Hepatocellular carcinoma; Liver failure; Splanchnic venous thrombosis

Mesh:

Year:  2016        PMID: 27026379     DOI: 10.1007/s11739-016-1416-8

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  25 in total

1.  Hemostatic abnormalities in cirrhosis and tumor-related portal vein thrombosis.

Authors:  Huseyin Alkim; Selime Ayaz; Nurgul Sasmaz; Perihan Oguz; Burhan Sahin
Journal:  Clin Appl Thromb Hemost       Date:  2011-12-13       Impact factor: 2.389

Review 2.  The coagulopathy of chronic liver disease.

Authors:  Armando Tripodi; Pier Mannuccio Mannucci
Journal:  N Engl J Med       Date:  2011-07-14       Impact factor: 91.245

3.  Portal vein thrombosis and chronic liver disease progression: The closer you look the more you see.

Authors:  Edoardo G Giannini; R Todd Stravitz; Stephen H Caldwell
Journal:  Hepatology       Date:  2015-06-19       Impact factor: 17.425

4.  Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study.

Authors:  Filipe Nery; Sylvie Chevret; Bertrand Condat; Emmanuelle de Raucourt; Larbi Boudaoud; Pierre-Emmanuel Rautou; Aurelie Plessier; Dominique Roulot; Cendrine Chaffaut; Valerie Bourcier; Jean-Claude Trinchet; Dominique-Charles Valla
Journal:  Hepatology       Date:  2015-01-05       Impact factor: 17.425

Review 5.  Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats.

Authors:  Ton Lisman; Pieter W Kamphuisen; Patrick G Northup; Robert J Porte
Journal:  J Hepatol       Date:  2013-03-30       Impact factor: 25.083

Review 6.  Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction?

Authors:  F Violi; S Basili; V Raparelli; P Chowdary; A Gatt; A K Burroughs
Journal:  J Hepatol       Date:  2011-06-28       Impact factor: 25.083

Review 7.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

8.  Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism.

Authors:  Patrick G Northup; Matthew M McMahon; A Parker Ruhl; Scott E Altschuler; Agata Volk-Bednarz; Stephen H Caldwell; Carl L Berg
Journal:  Am J Gastroenterol       Date:  2006-07       Impact factor: 10.864

Review 9.  Systematic review: portal vein thrombosis in cirrhosis.

Authors:  E A Tsochatzis; M Senzolo; G Germani; A Gatt; A K Burroughs
Journal:  Aliment Pharmacol Ther       Date:  2009-10-23       Impact factor: 8.171

10.  The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients.

Authors:  Abdulaziz Aldawood; Yaseen Arabi; Abdulrahman Aljumah; Alawi Alsaadi; Asgar Rishu; Hasan Aldorzi; Saad Alqahtani; Mohammad Alsultan; Afaf Felemban
Journal:  Thromb J       Date:  2011-01-18
View more
  26 in total

Review 1.  Portal vein thrombosis: A concise review (Review).

Authors:  Raluca S Costache; Andreea S Dragomirică; Elena A Dumitraș; Jinga Mariana; Ana Căruntu; Andrada Popescu; Daniel O Costache
Journal:  Exp Ther Med       Date:  2021-05-13       Impact factor: 2.447

Review 2.  Management of Non-tumoral Portal Vein Thrombosis in Patients with Cirrhosis.

Authors:  Jonathan G Stine; Patrick G Northup
Journal:  Dig Dis Sci       Date:  2019-03       Impact factor: 3.199

Review 3.  Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis.

Authors:  Xiangbo Xu; Xiaozhong Guo; Valerio De Stefano; Gilberto Silva-Junior; Hemant Goyal; Zhaohui Bai; Qingchun Zhao; Xingshun Qi
Journal:  Hepatol Int       Date:  2019-06-07       Impact factor: 6.047

4.  The clinical value of color Doppler ultrasonography in measuring the hemodynamics of liver cirrhosis patients' portal and splenic veins.

Authors:  Ran Hui; Zhe Li; Zongjie Liu; Xiuping Liu; Heping Deng
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

Review 5.  Portal vein thrombosis - a primer for the general physician.

Authors:  Mohammad Haris; Jecko Thachil
Journal:  Clin Med (Lond)       Date:  2017-06       Impact factor: 2.659

6.  Portal vein thrombosis in patients with cirrhosis: underdiagnosis and undertreatment?

Authors:  Aaron Liew; James Douketis
Journal:  Intern Emerg Med       Date:  2016-05-23       Impact factor: 3.397

Review 7.  Anticoagulation in patients with advanced liver disease: an open issue.

Authors:  Francesco Violi; Lorenzo Loffredo; Daniele Pastori
Journal:  Intern Emerg Med       Date:  2020-10-18       Impact factor: 3.397

8.  Timing of Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: An Italian Internist's Perspective.

Authors:  Nicoletta Riva; Walter Ageno
Journal:  J Transl Int Med       Date:  2018-03-28

9.  Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study.

Authors:  S Basili; V Raparelli; L Napoleone; G Talerico; G R Corazza; F Perticone; D Sacerdoti; A Andriulli; A Licata; A Pietrangelo; A Picardi; G Raimondo; F Violi
Journal:  Am J Gastroenterol       Date:  2017-12-19       Impact factor: 10.864

Review 10.  Transjugular intrahepatic portosystemic shunt (TIPS): current indications and strategies to improve the outcomes.

Authors:  Francesco Vizzutti; Filippo Schepis; Umberto Arena; Fabrizio Fanelli; Stefano Gitto; Silvia Aspite; Laura Turco; Gabriele Dragoni; Giacomo Laffi; Fabio Marra
Journal:  Intern Emerg Med       Date:  2020-01-09       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.